

Asymmetric Total Synthesis of Mycobacterial Diacyl Trehaloses Demonstrates a Role for Lipid Structure in Immunogenicity

Mira Holzheimer, Josephine F. Reijneveld,[▽] Alexandra K. Ramnarine,[▽] Georgios Misiakos, David C. Young, Eri Ishikawa, Tan-Yun Cheng, Sho Yamasaki, D. Branch Moody, Ildiko Van Rhijn,* and Adriaan J. Minnaard*



Cite This: *ACS Chem. Biol.* 2020, 15, 1835–1841



Read Online

ACCESS |




Metrics & More



Article Recommendations



Supporting Information



ABSTRACT: The first asymmetric total synthesis of three structures proposed for mycobacterial diacyl trehaloses, DAT₁, DAT₂, and DAT₃ is reported. The presence of two of these glycolipids, DAT₁ and DAT₃, within different strains of pathogenic *M. tuberculosis* was confirmed, and it was shown that their abundance varies significantly. In mass spectrometry, synthetic DAT₂ possessed almost identical fragmentation patterns to presumptive DAT₂ from *Mycobacterium tuberculosis* H37Rv, but did not coelute by HPLC, raising questions as to the precise relationship of the synthetic and natural materials. The synthetic DATs were examined as agonists for signaling by the C-type lectin, Mincle. The small differences in the chemical structure of the lipidic parts of DAT₁, DAT₂, and DAT₃ led to drastic differences of Mincle binding and activation, with DAT₃ showing similar potency as the known Mincle agonist trehalose dimycolate (TDM). In the future, DAT₃ could serve as basis for the design of vaccine adjuvants with simplified chemical structure.

INTRODUCTION

Mycobacterium tuberculosis (*Mtb*), which is the causative agent of the disease tuberculosis (Tb), is responsible for the largest number of deaths worldwide by a single pathogen, killing an estimated 1.3 million people annually. The ability of *Mtb* to survive and persist in the host is estimated to result in billions of latently infected individuals worldwide, with a high incidence of undiagnosed cases.¹ After infection of macrophages, *Mtb* is able to survive and replicate in host phagosomes, while withstanding the hostile acidic environment. The mycobacterial cell envelope is one factor that contributes to the resilience of *Mtb* within host cells.² It is a multilayered barrier, composed of many complex lipids, glycolipids, and glycoproteins, many of which are unique to *Mtb*.^{3–5} In the last decades, it has been shown that many of these cell wall components have antigenic properties and/or possess immunomodulatory functions. One class of these mycobacterial cell wall components, which consists of diacylated and polyacylated trehaloses, is suggested to be located on the outer part of the mycobacterial cell wall.⁶ These trehalose-based glycolipids are esterified with palmitic or stearic acid at the 2- and 2'-position, as well as with the *Mtb*-specific multimethyl-branched acyl residues phthioceranic acid,

hydroxyphthioceranic acid, mycosanoic acid, mycolipanic acid, and mycolipenic acid. Important examples are Ac2SGL,^{7–9} Sulfolipid-1,^{10–12} trehalose monomycolate and dimycolate,^{13,14} diacyl trehaloses (DAT),^{15–17} and pentaacyl trehaloses (PAT).^{15,18} Because of the chemical diversity of DAT and the potential for contamination of even small amounts of bioactive molecular variants, testing natural DAT compounds on cells for immune response is not reliable. To establish the molecular structure of these compounds and enable further biological studies, several of the compounds have been the target of total synthesis. In DAT and PAT, both of which have escaped total synthesis until now, the trehalose core is acylated with the methyl-branched fatty acids mycosanoic acid, mycolipanic acid, and mycolipenic acid (see Figure 1).^{17,18}

Received: January 14, 2020

Accepted: April 15, 2020

Published: April 15, 2020






Figure 1. (A) Chemical structures of the mycobacterial diacyl trehaloses DAT₁, DAT₂, and DAT₃. (B) Retrosynthetic analysis.

DAT was first isolated in 1989 by Daffé et al. and was initially named SL-IV (Sulfolipid-IV), since the structure was first assigned as 2,3-diacyl-trehalose-2'-sulfate.^{15,16} The structure of this family of acyl trehaloses was eventually revisited and corrected to be 2,3-diacyl-trehalose, and depending on the nature of the 3-O-acyl group, were termed DAT₁, DAT₂, or DAT₃ (see Figure 1A). In the following reports, these compounds were often referenced as just DAT, presenting a family of mycobacterial glycolipids rather than defined molecular structures.¹⁷ Many studies have asserted the antigenic properties of DAT glycolipids by ELISA, but these were tested mainly as mixtures rather than pure compounds. It was demonstrated multiple times that anti-DAT antibodies are present in blood sera of Tb patients but not of healthy controls.^{17,19–22} This raised great interest in using DAT for the detection and diagnosis of Tb in patients. The reports utilizing ELISA for the detection of anti-DAT antibodies, however, showed a huge variation in sensitivity and specificity, depending on assay design.²³


In recent years, research has focused on elucidating the biosynthesis of DAT and unravelling its effect on the immune

system.^{24–27} It was shown that DAT partially inhibits the proliferation of murine T-cells, suggesting a role in immunosuppression and T-cell hypo-responsiveness associated with Tb.²⁸ *Mtb* mutants incapable of synthesizing mycolipenic acid, and therefore deficient in DAT and PAT, show aggregation in liquid culture, because of defects in capsule attachment, indicating that one of the functions of DAT and PAT is anchoring the hydrophilic capsule to the hydrophobic mycolic acid layer of the mycobacterial cell envelope.^{24,29–31} However, in aerosol infection mouse models using DAT/PAT-deficient mutants, there were no observed differences in growth, compared to wild-type compounds, suggesting that DAT/PAT itself is not necessary for *Mtb* survival.²⁹

Recently, *Mtb* cell wall components—such as trehalose dimycolate (TDM, also known as cord factor)—have been identified as high-affinity ligands for macrophage-inducible C-type lectin (Mincle).^{32–34} The activation of Mincle results in downstream expression of cytokines, chemokines, and growth factors and leads to recruitment of inflammatory cells to the site of activation as a central part of the innate immune response to *Mtb*.³³ Several other *Mtb* cell wall glycolipids have been identified as Mincle activators,^{34,35} and there is growing interest in using these Mincle ligands for the development of novel vaccine adjuvants.³⁶

In 2017, it was demonstrated that a DAT-containing extract from *Mtb* also activated Mincle.³⁵ We realized that, apart from minute amounts of contaminants in natural isolates that can influence the results, the activation of Mincle could very well be dependent on the precise structure of the DAT. Therefore, we sought to synthesize three different DATs with precisely defined molecular structure and stereochemistry to study their Mincle activating properties and to assess the influence of the acyl substituents on Mincle binding. Furthermore, we aimed to confirm the presence of these three DATs in different strains of *Mtb*, including clinical isolates.

Scheme 1. Asymmetric Synthesis of Mycosanoic Acid (2), Mycolipanic Acid (3), and Mycolipenic Acid (4)



RESULTS AND DISCUSSION


Synthesis. DAT₁, DAT₂, and DAT₃ differ in their chiral acyl group esterified with the 3-OH of the trehalose core. Therefore, our synthesis plan involved the preparation of suitably protected 2-palmitoyl trehalose **1** and the three mycobacterial lipids **2**, **3**, and **4** as key intermediates necessary to construct the target diacyl trehaloses. Trehalose **1** could be obtained starting from α,α -trehalose by a desymmetrization approach previously applied in the synthesis of trehalose-based sulfoglycolipids.^{37,38} The mycobacterial lipids, on the other hand, can be traced back to the common precursor **5** (Figure 1B). The synthesis of mycolipanic and mycolipenic acid was previously reported by us and involves copper-catalyzed asymmetric conjugate addition (Cu-cat. ACA) and an Evans' aldol reaction to introduce the stereocenters.³⁹ We sought to improve the current synthetic procedures to arrive at an efficient, high-yielding total synthesis.

The synthesis of the chiral enantiopure lipids **2**, **3**, and **4** (see Scheme 1) commenced with Cu-cat. ACA of methylmagnesium bromide to α,β -unsaturated thioester **5** giving **6** in 81% yield and 98% enantiomeric excess (ee). Reduction to the corresponding aldehyde, followed by Horner–Wadsworth–Emmons reaction, produced another α,β -unsaturated thioester **7**. The second methyl stereocenter was again introduced by Cu-cat. ACA in excellent yield and diastereomeric ratio (dr). Double DIBAL-H reduction, followed by tosylation, gave **9** in 88% yield over three steps. Tosylate **9** was subjected to a Grignard cross-coupling in the presence copper(I) to install the linear alkyl tail of **10**. Removal of the silyl protecting group, followed by Dess–Martin oxidation, gave aldehyde **11** in an excellent yield of 97% over two steps. From **11**, all three mycobacterial lipids could be synthesized in a limited number of steps. Mycosanoic acid **2** was obtained in 92% yield after Pinnick oxidation of aldehyde **11**. Mycolipenic acid **4** was prepared by first subjecting **11** to a Wittig reaction, followed by alkaline ester hydrolysis. To install the two remaining stereocenters present in **3**, an Evans' aldol reaction was performed, giving **13** in good yield and excellent dr. The aldol product **13** was finally hydrolyzed to give mycolipanic acid **3**. Compared to the previous syntheses of **3** and **4**, the yields could be significantly improved by careful optimization of the reactions. For mycosanoic acid, mycolipanic acid, and mycolipenic acid, excellent overall yields were obtained with 53% over 10 steps, 47% (previously 2%) over 11 steps, and 46% (previously 5%) over 11 steps, respectively, making the synthesis of these chiral lipids highly efficient. In the synthesis of mycolipenic acid, oxidation, Wittig reaction, and ester hydrolysis were significantly improved, whereas in the case of mycolipanic acid, the Evans' aldol reaction and the removal of the chiral auxiliary were optimized to give high yields.³⁹

With the enantiopure acids **2–4** in hand, the esterification of palmitoylated trehalose **1** was achieved by following the Yamaguchi procedure. In the case of mycosanoic acid and mycolipenic acid, the corresponding diacylated products were obtained in good yields; however, in order to reach that result for mycolipanic acid, the esterification procedure needed to be carefully optimized to avoid acyl migration and elimination of the β -hydroxyl of **3**. By limiting the number of equivalents of base and keeping the time for acid activation at a minimum, synthesis of **14b** could be achieved in good yield. Notably, in the case of **14a** and **14c**, no acyl migration was observed, indicating that the β -hydroxyl in **3** might play a role in acyl

migration. Removal of the silyl protecting group of **14a–14c** under buffered conditions gave the corresponding diols **15a–15c** in good to excellent yields. The final deprotection—the removal of the benzylidene protecting group—was achieved by applying a procedure that was reported by Guiard et al.,³⁷ using aqueous sulfuric acid (DAT₁ and DAT₃) or by palladium hydrogenolysis (DAT₂, to prevent β -hydroxyl elimination) and provided the three di-O-acyl trehaloses DAT₁, DAT₂, and DAT₃ in moderate to good yields. (See Scheme 2.) The

Scheme 2. Completion of the Total Synthesis of the Mycobacterial Glycolipids DAT₁, DAT₂, and DAT₃



spectral data of DAT₁ matched the reported NMR data of isolated DAT_{1a}.¹⁷ Besra's report describes the ¹H NMR signals of the anomeric protons of DAT₁ at 5.25 and 5.05 ppm for the acylated and nonacylated glucose unit, respectively. The spectrum of synthetic DAT₁ shows these two anomeric signals at 5.24 and 5.06 ppm, which is in good agreement. Furthermore, H-2 and H-3 (at the positions bearing the acyl moieties) in natural DAT₁ appear at 4.83 and 5.40 ppm, respectively, and in synthetic DAT₁ at 4.82 and 5.39 ppm, respectively. The ¹³C signals of the anomeric carbons in natural DAT₁ are reported at 95.0 and 92.0 ppm. In the synthetic material, these signals can be found 94.6 and 91.7 ppm, again in good agreement. In addition, the carbonyl carbon signals in synthetic DAT₁ resonate at 173.5 and 177.6 ppm and the corresponding signals in natural DAT₁ can be found at 173.8 and 177.8 ppm. All in all, these data leave us confident that the structure of synthetic DAT₁ is identical to that of natural DAT₁, as described by Besra (for more detailed NMR signal comparison, see the Supporting Information). As for synthetic DAT₂ and DAT₃, the structural identity is beyond reasonable doubt, because the structures of the lipid components have been previously established³⁹ and the nuclear magnetic resonance (¹H NMR and ¹³C NMR) and mass spectra showed patterns very similar to those of synthetic and natural DAT₁.

Detection of DAT₁, DAT₂, and DAT₃ in *Mtb* Strains. Having completed the total synthesis of DAT₁, DAT₂, and DAT₃ with structures as described in the literature,¹⁷ we sought to determine if the synthesized glycolipids match the structures of natural products present in virulent strains of *Mtb*. Mycobacterial lipid extracts of the reference strain H37Rv and three clinical isolates j257, j011, and j117 were analyzed by

means of LC-MS. The extracted-ion chromatograms (Figure 2A) suggest that all three DATs are produced by the laboratory strain H37Rv. Ions consistent with DAT₁ and DAT₂ were only reliably detected in the H37Rv strain, whereas DAT₃ could be detected in all four strains. The corresponding mass spectra of the detected natural DATs matched the calculated m/z of each compound within the expected experimental error of 3–4 ppm. Collision-induced fragmentation (see the data given in the Supporting Information) of the natural and synthetic DATs yielded interpretable cleavages (Figure 2C, H-transfers not shown) that supported the general structures and connectivity. Co-injection (Figure 2B) of synthetic standards and natural lipid mixtures showed a chromatographic match for DAT₁ and DAT₃. However, synthetic DAT₂ eluted more than a minute earlier than the natural compound. Thus, whereas the identity of DAT₁ and DAT₃ can be considered to have been established beyond a reasonable doubt, we conclude that material with the structure of synthetic DAT₂ does not occur in the H37Rv strain. This may mean that an isomer of the proposed structure of DAT₂ is present in this strain, or that the structure of natural DAT₂ has been incorrectly assigned.¹⁵

Mincle Activation by DAT₁, DAT₂, and DAT₃. We decided to assess the Mincle activating properties of the synthetic DATs as well (see Figure 3), keeping in mind that our synthetic DAT₂ was not present in the studied *Mtb* strains. Mincle activation was compared to the known Mincle-agonist TDM, which is highly potent. Previous studies have identified various lipidlike trehaloses that activate Mincle, so we expected that all three forms of DAT, which differ in small ways in their alkyl chains, were good candidate activators. Prior to the functional assays, TLC analysis of synthetic DAT₁, DAT₂, and DAT₃ was performed to exclude the presence of glycolipid degradation products and quantification errors (Figure 3A). Mincle activation requires the adaptor protein FcR γ . Therefore, functional Mincle-activation assays were performed by treatment of NFAT-GFP reporter cells expressing murine Mincle and FcR γ (Figure 3B) or human Mincle and FcR γ (Figure 3C) with the synthetic DAT variants and TDM. In both assays, DAT₃ was able to activate Mincle. In the case of human Mincle, DAT₃ showed similar potency to the highly potent agonist TDM. DAT₂ and, remarkably, DAT₁ only weakly activated murine Mincle. When using human Mincle-expressing cells, DAT₂ showed moderate activation, whereas DAT₁ again barely induced Mincle stimulation. In an independent experiment, an ELISA-based technique was applied that was dependent not on cellular activation but only on the detection of physical interaction between DAT and soluble Mincle proteins (Figure 3D). Strong binding of murine Mincle to DAT₃ was observed, but only minimal binding to DAT₁ and DAT₂, thereby confirming the results obtained in the cellular activation assay. These results provide evidence that the chemical structure of the 3-*O*-acyl substituent (either mycosanoic acid, mycolipanic acid, or mycolipenic acid) strongly influences Mincle binding and activation.

CONCLUSIONS

In this study, we have accomplished the first total synthesis of three structurally related mycobacterial DATs. These synthetic DATs were used as a reference in the detection of natural DATs in *Mtb* by liquid chromatography–mass spectroscopy. This showed that the presence and abundance of DAT₁ and DAT₃ differs strongly, dependent on the *Mtb* strain. This has important consequences for the potential use of DATs as




Figure 2. Detection of DAT variants in *M. tuberculosis* strains. Lipid extracts from four different *M. tuberculosis* strains were analyzed via high-performance liquid chromatography–mass spectroscopy (HPLC-MS): laboratory strain H37Rv, and three clinical isolates named j257, j011, and j117. Extracted ion chromatograms of ions corresponding with the ammonium adduct of DAT₁ (calculated m/z = 948.733), DAT₂ (m/z = 1006.775), and DAT₃ (m/z = 988.764) showed m/z values consistent with those expected from DATs. (B) Comparison with synthetic standards showed chromatographic coelution for DAT₁ and DAT₃ but not for DAT₂, indicating that synthetic DAT₂ is not identical to natural DAT₂. (C) CID analysis of the standards and natural compounds (see data given in the Supporting Information) yielded fragmentation patterns diagnostic for the known structures.




Figure 3. Synthetic DAT₃ is recognized by human and mouse Mincle. (A) Before functional assays, DAT₁, DAT₂, and DAT₃ were analyzed by thin-layer chromatography for relative quantification and the presence of major breakdown products. (B and C) NFAT-GFP reporter cells expressing mouse Mincle + FcR γ or human Mincle + FcR γ were stimulated with the indicated amount of DAT₁, DAT₂, DAT₃, or TDM. After 24 h, induction of NFAT-GFP was analyzed by flow cytometry. (D) ELISA-based detection of DAT₁, DAT₂, DAT₃, or TDM by mouse Mincle-human Ig Fc (mMincle-hIg) fusion proteins. Bound protein was detected with antihuman Ig-horse radish peroxidase (HRP), followed by the addition of a colorimetric substrate and measurement.

markers for Tb infection. In addition, it might explain *a posteriori* the irreproducibility observed in the many attempts to reliably detect DAT by ELISA. It also showed that the proposed structure of DAT₂ does not occur in the studied strains, including the H37Rv strain. An alternative explanation is that the structure of DAT₂ has been assigned incorrectly, since, because of the lack of literature NMR data, a comparison with our synthetic material was not possible. This will be further investigated.

We found that small changes in the structure of the branched acyl chain in DAT lead to large differences in recognition by Mincle. It has been shown previously by Decout et al. that one of the molecular requirements for Mincle recognition, besides the trehalose or glucose scaffold, is the presence of two alkyl chains, either as two separate esters or as one fatty acid ester with an alkyl chain branched α to the carbonyl. Moreover, it was previously demonstrated that the lipid chains can be significantly shorter than the C80 lipids present in TDM. For instance, the synthetic Mincle ligand GlcC14C18, a glucose esterified at the 6-position with a C18 alkyl tail with a C14 alkyl branch on the α -position, shows even higher potency than TDM.³⁵ In addition, in a previous report, Mincle activation by β -glucosylceramide, which also contains an unsaturation in the lipid chain, was demonstrated.⁴⁰ Here,

we show that the presence of the α,β -unsaturation in DAT₃ enhances Mincle activation drastically, compared to the saturated counterpart DAT₁. This leads us to speculate that the double bond either serves as a point of interaction (such as π - π -stacking) with parts of the Mincle binding pocket or induces a specific conformation beneficial for binding. All in all, one might conclude that DAT₃ could be an alternative starting point for adjuvant design for TDM, given the higher complexity and lipophilicity of the latter. For future development of *Mtb* vaccine adjuvants, even simpler DAT analogues could be designed without chiral methyl branches or based on glucose rather than trehalose.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acscchembio.0c00030>.

Synthetic procedures, LC-MS protocols, Mincle functional and binding assay protocols, compound data (¹H and ¹³C NMR, HRMS) (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Ildiko Van Rhijn – Brigham and Women's Hospital Division of Rheumatology, Immunology and Allergy and Harvard Medical School, Boston, Massachusetts 02115, United States; Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, The Netherlands; Email: i.vanrhijn@uu.nl

Adriaan J. Minnaard – Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands; orcid.org/0000-0002-5966-1300; Email: a.j.minnaard@rug.nl

Authors

Mira Holzheimer – Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands; orcid.org/0000-0003-2157-0136

Josephine F. Reijneveld – Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands; Brigham and Women's Hospital Division of Rheumatology, Immunology and Allergy and Harvard Medical School, Boston, Massachusetts 02115, United States; Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, The Netherlands

Alexandrea K. Ramnarine – Brigham and Women's Hospital Division of Rheumatology, Immunology and Allergy and Harvard Medical School, Boston, Massachusetts 02115, United States

Georgios Misiakos – Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands

David C. Young – Brigham and Women's Hospital Division of Rheumatology, Immunology and Allergy and Harvard Medical School, Boston, Massachusetts 02115, United States

Eri Ishikawa – Department of Molecular Immunology, Research Institute for Microbial Diseases and Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan

Tan-Yun Cheng – Brigham and Women's Hospital Division of Rheumatology, Immunology and Allergy and Harvard Medical School, Boston, Massachusetts 02115, United States

Sho Yamasaki – Department of Molecular Immunology, Research Institute for Microbial Diseases and Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan

D. Branch Moody – Brigham and Women's Hospital Division of Rheumatology, Immunology and Allergy and Harvard Medical School, Boston, Massachusetts 02115, United States

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acscchembio.0c00030>

Author Contributions

^VThese authors contributed equally.

Funding

This work was supported by the Dutch Science Foundation (NWO), the Bill and Melinda Gates Foundation, and AMED (Nos. JP19gm0910010 and JP19ak0101070).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank T. Tiemersma, R. Sneep, and P. van der Meulen (University of Groningen) for assistance on analyses.

REFERENCES

- (1) World Health Organization. (2018) *Global Tuberculosis Report 2018* (ISBM No. 978-92-4-156564-6).
- (2) Ehrt, S., and Schnappinger, D. (2009) Mycobacterial survival strategies in the phagosome: defence against host stresses. *Cell. Microbiol.* 11 (8), 1170.
- (3) Barry, C. E., III, Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, R. A., and Yuan, Y. (1998) Mycolic Acids: Structure, Biosynthesis and Physiological Functions. *Prog. Lipid Res.* 37 (2-3), 143.
- (4) Karakousis, P. C., Bishai, W. R., and Dorman, S. E. (2004) Mycobacterium tuberculosis cell envelope lipids and the host immune response. *Cell. Microbiol.* 6 (2), 105.
- (5) Singh, P., Rameshwar, N. R., Ghosh, S., and Mukhopadhyay, S. (2018) Cell envelope lipids in the pathophysiology of Mycobacterium tuberculosis. *Future Microbiol.* 13 (6), 689.
- (6) Ortalo-Magné, A., Lemassu, A., Lanéelle, M.-A., Bardou, F., Silve, G., Gounon, P., Marchal, G., and Daffé, M. (1996) Identification of the Surface-Exposed Lipids on the Cell Envelopes of Mycobacterium tuberculosis and Other Mycobacterial Species. *J. Bacteriol.* 178, 456.
- (7) Mougous, J. D., Leavell, M. D., Senaratne, R. H., Leigh, C. D., Williams, S. J., Riley, L. W., Leary, J. A., and Bertozzi, C. R. (2002) Discovery of sulfated metabolites in mycobacteria with a genetic and mass spectrometric approach. *Proc. Natl. Acad. Sci. U. S. A.* 99 (26), 17037.
- (8) Gilleron, M., Stenger, S., Mazon, Z., Wittke, F., Mariotti, S., Böhmer, G., Prandi, J., Mori, L., Puzo, G., and De Libero, G. (2004) Diacylated Sulfoglycolipids Are Novel Mycobacterial Antigens Stimulating CD1-restricted T Cells during Infection with Mycobacterium tuberculosis. *J. Exp. Med.* 199 (5), 649.
- (9) Geerdink, D., Horst, B. t., Lepore, M., Mori, L., Puzo, G., Hirsch, A. K. H., Gilleron, M., de Libero, G., and Minnaard, A. J. (2013) Total synthesis, stereochemical elucidation and biological evaluation of Ac2SGL; a 1,3-methyl branched sulfoglycolipid from Mycobacterium tuberculosis. *Chem. Sci.* 4 (2), 709.
- (10) Goren, M. B. (1970) Sulfolipid Di of Mycobacterium Tuberculosis, Strain H37RvII. Structural Studies. *Biochim. Biophys. Acta, Lipids Lipid Metab.* 210, 127.
- (11) Goren, M. B., Brokl, O., Das, B. C., and Lederer, E. (1971) Sulfolipid I of Mycobacterium tuberculosis, Strain H37Rv. Nature of the Acyl Substituents. *Biochemistry* 10, 72.
- (12) Geerdink, D., and Minnaard, A. J. (2014) Total synthesis of sulfolipid-1. *Chem. Commun.* 50 (18), 2286.
- (13) Noll, H., Bloch, H., Asselineau, J., and Lederer, E. (1956) The chemical structure of the cord factor of Mycobacterium tuberculosis. *Biochim. Biophys. Acta* 20, 299.
- (14) Ryll, R., Kumazawa, Y., and Yano, I. (2001) Immunological Properties of Trehalose Dimycolate (Cord Factor) and Other Mycolic Acid-Containing Glycolipids – A Review. *Microbiol. Immunol.* 45 (12), 801.
- (15) Minnikin, D. E., Dobson, G., Sesardic, D., and Ridell, M. (1985) Mycolipenates and Mycolipanulates of Trehalose from Mycobacterium tuberculosis. *Microbiology* 131, 1369.
- (16) Daffé, M., Papa, F., Laszlo, A., and David, H. L. (1989) Glycolipids of Recent Clinical Isolates of Mycobacterium tuberculosis: Chemical Characterization and Immunoreactivity. *Microbiology* 135, 2759.
- (17) Besra, G. S., Bolton, R. C., McNeil, M. R., Ridell, M., Simpson, K. E., Glushka, J., van Halbeek, H., Brennan, P. J., and Minnikin, D. E. (1992) Structural Elucidation of a Novel Family of Acyltrehaloses from Mycobacterium tuberculosis. *Biochemistry* 31, 9832.
- (18) Daffé, M., Lacave, C., Lanéelle, M.-A., Gillois, M., and Lanéelle, G. (1988) Polyphthienoyl trehalose, glycolipids for virulent strains of the tubercle bacillus. *Eur. J. Biochem.* 172, 579.
- (19) Martín-Casabona, N., Gonzalez Fuente, T., Papa, F., Rosselló Urgell, J., Vidal Plá, R., Codina Grau, G., and Ruiz Camps, I. (1992) Time Course of Anti-SL-IV Immunoglobulin G Antibodies in Patients with Tuberculosis-Associated AIDS. *J. Clin. Microbiol.* 30 (5), 1089.
- (20) Papa, F., Luquin, M., and David, H. L. (1992) DOT-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of Mycobacterium tuberculosis. *Res. Microbiol.* 143, 327.
- (21) Tórtola, M. T., Lanéelle, M. A., and Martín-Casabona, N. (1996) Comparison of Two 2,3-Diacyl Trehalose Antigens from Mycobacterium tuberculosis and Mycobacterium fortuitum for Serology in Tuberculosis Patients. *Clin. Diagn. Lab. Immunol.* 3 (5), 563.
- (22) Muñoz, M., Lanéelle, M.-A., Luquin, M., Torrelles, J., Julián, E., Ausina, V., and Daffé, M. (1997) Occurrence of an antigenic triacyl trehalose in clinical isolated and reference strains of Mycobacterium tuberculosis. *FEMS Microbiol. Lett.* 157, 251.
- (23) Julián, E., Cama, M., Martínez, P., and Luquin, M. (2001) An ELISA for five glycolipids from the cell wall of Mycobacterium tuberculosis: Tween 20 interference in the assay. *J. Immunol. Methods* 251, 21.
- (24) Dubey, V. S., Sirakova, P. E., and Kolattukudy, P. E. (2002) Disruption of msl3 abolishes the synthesis of mycolipanoic and mycolipenic acids required for polyacyltrehalose synthesis in Mycobacterium tuberculosis H37Rv and causes cell aggregation. *Mol. Microbiol.* 45 (2), 1451.
- (25) Gonzalo-Asensio, J., Mostowy, S., Harders-Westerveen, J., Huygen, K., Hernandez-Pando, R., Thole, J., Behr, M., Gicquel, B., and Martin, C. PhoP (2008) A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence. *PLoS One* 3 (10), No. e3496.
- (26) Hatzios, S. K., Schelle, M. W., Holsclaw, C. M., Behrens, C. R., Botyanszki, Z., Lin, F. L., Carlson, B. L., Kumar, P., Leary, J. A., and Bertozzi, C. R. (2009) PapA3 is an Acyltransferase Required for Polyacyltrehalose Biosynthesis in Mycobacterium tuberculosis. *J. Biol. Chem.* 284 (19), 12745.
- (27) Rodriguez, J. E., Ramirez, A. S., Salas, L. P., Helguera-Repetto, C., Gonzalez-y-Merchand, J., Soto, C. Y., and Hernandez-Pando, R. (2013) Transcription of Genes Involved in Sulfolipid and Polyacyltrehalose Biosynthesis of Mycobacterium tuberculosis in Experimental Latent Tuberculosis Infection. *PLoS One* 8 (3), No. e58378.
- (28) Saavedra, R., Segura, E., Leyva, R., Esparza, L. A., and Lopez-Marín, L. M. (2001) Mycobacterial Di-O-Acyl-Trehalose Inhibits Mitogen- and Antigen-Induced Proliferation of Murine T Cells In Vitro. *Clin. Diagn. Lab. Immunol.* 8 (6), 1081.
- (29) Rousseau, C., Neyrolles, O., Bordat, Y., Giroux, S., Sirakova, T. D., Prevost, M.-C., Kolattukudy, P. E., Gicquel, B., and Jackson, M. (2003) Deficiency in mycolipenate- and mycosanoate-derived

acyltrehaloses enhances early interactions of *Mycobacterium tuberculosis* with host cells. *Cell. Microbiol.* 5 (6), 405.

(30) Gonzalo Asensio, J., Maia, C., Ferrer, N. L., Barilone, N., Laval, F., Soto, C. Y., Winter, N., Daffe, M., Gicquel, B., Martin, C., Jackson, M., et al. (2006) The Virulence-associated Two-component PhoP-PhoR System Controls the Biosynthesis of Polyketide-derived Lipids in *Mycobacterium tuberculosis*. *J. Biol. Chem.* 281 (3), 1313.

(31) Walters, S. B., Dubnau, E., Kolesnikova, I., Laval, F., Daffe, M., and Smith, I. (2006) The *Mycobacterium tuberculosis* PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. *Mol. Microbiol.* 60 (2), 312.

(32) Ishikawa, E., Ishikawa, T., Morita, Y. S., Toyonaga, K., Yamada, H., Takeuchi, O., Kinoshita, T., Akira, S., Yoshikai, Y., and Yamasaki, S. (2009) Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. *J. Exp. Med.* 206 (13), 2879.

(33) Williams, S. J. (2017) Sensing Lipids with Mincle: Structure and Function. *Front. Immunol.* 8, 1662.

(34) Braganza, C. D., Teunissen, T., Timmer, M. S. M., and Stocker, B. L. (2018) Identification and Biological Activity of Synthetic Macrophage Inducible C-Type Lectin Ligands. *Front. Immunol.* 8, 1940.

(35) Decout, A., Silva-Gomes, S., Drocourt, D., Barbe, S., Andre, I., Cueto, F. J., Lioux, T., Sancho, D., Perouzel, E., et al. (2017) Rational design of adjuvants targeting the C-type lectin Mincle. *Proc. Natl. Acad. Sci. U. S. A.* 114 (10), 2675.

(36) Schoenen, H., Bodendorfer, B., Hitchens, K., Manzanero, S., Werninghaus, K., Nimmerjahn, F., Agger, E. M., Stenger, S., Andersen, P., et al. (2010) Cutting edge: Mincle is essential for recognition and adjuvant activity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. *J. Immunol.* 184 (6), 2756.

(37) Guiard, J., Collmann, A., Gilleron, M., Mori, L., De Libero, G., Prandi, J., and Puzo, G. (2008) Synthesis of Diacylated Trehalose Sulfates: Candidates for a Tuberculosis Vaccine. *Angew. Chem., Int. Ed.* 47 (50), 9734.

(38) Wu, C.-H., and Wang, C.-C. (2014) Strategies for desymmetrising trehalose to synthesise trehalose glycolipids. *Org. Biomol. Chem.* 12 (30), 5558.

(39) ter Horst, B., van Wermeskerken, J., Feringa, B. L., and Minnaard, A. J. (2010) Catalytic Asymmetric Synthesis of Mycolipenic and Mycolipanic Acid. *Eur. J. Org. Chem.* 2010, 38.

(40) Nagata, M., Izumi, Y., Ishikawa, E., Kiyotake, R., Doi, R., Iwai, S., Omahdi, Z., Yamaji, T., Miyamoto, T., et al. (2017) Intracellular metabolite beta-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity. *Proc. Natl. Acad. Sci. U. S. A.* 114 (16), No. E3285.